Kamfanin Biotechnology na Burtaniya MiNA Therapeutics ‘innovative RNA therapy may enhance liver cancer patients’ response to standard treatment. The therapy uses a double-stranded RNA that can activate a target gene called CEBPA. Packaging double-stranded RNA in lipid nanoparticles helps to penetrate into liver cells that are often difficult to reach and can control gene expression in the nucleus. It is understood that the low level expression of certain genes is related to liver ciwon daji and other liver diseases. In laboratory studies, increasing the expression of CEBPA to restore its protein levels to normal can help reduce the growth of cancer cells.
Daga cikin marasa lafiya da ke karɓar ƙananan RNA da aka kunna (saRNA), biyu daga cikinsu sun nuna cikakkiyar amsa bayan sun karbi sorafenib, ɗayan kuma ya nuna wani bangare na amsawa bayan jiyya tare da lenvatinib. Wannan shine gwajin farko na maganin saRNA a cikin mutane. Tun da har yanzu binciken yana kan matakin farko, kamfanonin fasahar kere kere a yanzu suna fatan tattara ƙarin shaidar da ta dace.
Har ila yau, kamfanin yana fatan gudanar da gwajin magani iri ɗaya ga majinyata masu fama da cutar cirrhosis a nan gaba, tare da haɗin gwiwar Boehringer Ingelheim don gudanar da wasu ayyuka na cututtukan hanta. Bayan dogon lokaci na haɓakawa, ƙarin jiyya na RNA sun shiga kasuwa. Ba kamar hanyoyin kwantar da hankali na MiNA waɗanda ke kunna maganganun kwayoyin halitta ba, galibi suna amfani da fasahar tsoma baki ta RNA (RNAi) don rage maganganun kwayoyin halitta. Kwanan nan, Hukumar Tarayyar Turai ta amince da Onpattro, maganin RNAi na farko wanda Alnylam ya kirkira don maganin polyneuropathy.
